News

The researchers say that the gene, caveolin-1 (Cav-1), could be a potential target for future drugs aimed at preventing breast cancer.

Collaboration to discover, develop and commercialise Nanobodies® directed at the tumour necrosis factor alpha protein and its receptors that target diseases in multiple therapeutic areas.

Scientists from Applied Biosystems presented data demonstrating the accuracy of TaqMan® Drug Metabolism Genotyping Assays in identifying variation in genes that code for drug metabolism enzymes.

The seminars focus on how advances in laboratory automation, using Laboratory Information Management Systems (LIMS), can act as a key enabler for improved productivity and quality in the process industry.

The seminars focus on how advances in laboratory automation, using Laboratory Information Management Systems (LIMS), can act as a key enabler for improved productivity and quality in the process industry.

Awarded by Promega Corporation, this certification validates an instrument to the highest performance levels and standards for the Dual-Luciferase® Reporter Assay System.

The Department of Bioengineering at UCSD has implemented the MassARRAY® system to conduct automated high throughput mutation detection in microbial genomes and mixed microbial populations.

IntegraGen is focused on the development of diagnostic and prognostic genetic tests for a range of complex diseases using its proprietary technology platform for gene identification.

The Selected Organic Reactions Database (SORD) is tapping into the vast reserves of chemical reaction information from academic research.

Technology rights cover ADVEXIN or INGN 241 plus EGF inhibitors such as Vectibix, Erbitux, Tarceva and Iressa.

The service is oriented to life science and nano industries.